Alexion Pharmaceuticals Inc.

This powerful committee controls taxation, trade, and entitlement spending (like Medicare). Its decisions on corporate tax policy and, critically, Medicare drug pricing directly impact the profitability and revenue streams of pharmaceutical companies.

This committee allocates federal discretionary spending, directly influencing the budgets of agencies like the FDA, NIH, and VA, which are crucial for pharmaceutical research, regulation, and procurement.

This committee has direct regulatory oversight of the FDA and NIH, which are primary bodies for drug approval, research funding, and pharmaceutical industry regulation, making it critically important for Alexion Pharmaceuticals.

This committee's oversight of antitrust laws and intellectual property is critical for pharmaceutical companies, impacting mergers and acquisitions, patent protections, and competition within the industry.

Although advisory, this committee's investigations and hearings on drug pricing and healthcare costs for older Americans create significant headline risk and can directly influence public sentiment and future legislative pressure on pharmaceutical companies.

Funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and the procurement of pharmaceutical products for veterans, which is a significant market segment.